MSD wins patent extension feud over post-surgery drug

15-06-2023

Muireann Bolger

MSD wins patent extension feud over post-surgery drug

Atmosphere1 / Shutterstock.com

The three-year dispute revolved around proposed generic versions of a drug used to offset the effects of muscle relaxants | Pharma giant can retain patent until January 2026.


patent, drug, extension, Bridion, generic, muscle relaxants,, MSD, Merck, Hatch-Waxman, post-surgery drug, feud, infringement, sugammadex, pharma

LSIPR